AMPICILLIN+CLOXACILLIN

This brand name is authorized in Nigeria.

Active ingredients

The drug AMPICILLIN+CLOXACILLIN contains a combination of these active pharmaceutical ingredients (APIs):

1	Ampicillin UNII 7C782967RD - AMPICILLIN
	Ampicillin is a broad spectrum penicillin, indicated for the treatment of a wide range of bacterial infections caused by ampicillin sensitive organisms.
	Read more about Ampicillin
2	Cloxacillin UNII 65LCB00B4Y - CLOXACILLIN SODIUM
	Cloxacillin is a semi-synthetic beta-lactamase resistant penicillin with activity against gram-negative and gram-positive bacteria including beta-lactamase producing staphylococci. Cloxacillin acts by interfering with the formation of new bacterial cell wall by dividing organisms.
	Read more about Cloxacillin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
C4-1157	Capsule	Ampicillin and Cloxacillin Capsules CAP 250 mg; 250 mg	Each capsule contains: Ampicillin Trihydrate BP equiv. to Ampicillin 250 mg, Cloxacillin Sodium BP equiv. to Cloxacillin 250 mg	10/11/2020
C4-1209	Capsule	Softhealth Ampicillin and Cloxacillin Capsules CAP 250 mg; 250 mg	Each capsule contains: Ampicillin (as Ampicillin Trihydrate BP) 250 mg, Cloxacillin (as Cloxacillin Sodium) 250 mg	10/11/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01CR01	Ampicillin and enzyme inhibitor	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01C Beta-lactam antibacterials, penicillins → J01CR Combinations of penicillins, incl. beta-lactamase inhibitors
Discover more medicines within J01CR01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	C4-1157, C4-1209